Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for REGN
512.56
+0.44 (0.09%)
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 509.45 - 517.18
52 week 269.50 - 519.46
Open 509.51
Vol / Avg. 763,502.00/796,773.00
Mkt cap 52.94B
P/E 162.56
Div/yield     -
EPS 3.15
Shares 101.31M
Beta 0.87
Inst. own 73%
Aug 3, 2015
Q2 2015 Regeneron Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 12, 2015
Regeneron Pharmaceuticals Inc Annual Shareholders Meeting - 10:30AM EDT - Add to calendar
May 27, 2015
Regeneron Pharmaceuticals Inc at Sanford C Bernstein Strategic Decisions Conference
May 12, 2015
Regeneron Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 Regeneron Pharmaceuticals Inc Earnings Release
May 7, 2015
Q1 2015 Regeneron Pharmaceuticals Inc Earnings Call - Webcast
Mar 11, 2015
Regeneron Pharmaceuticals Inc at Barclays Healthcare Conference
Mar 3, 2015
Regeneron Pharmaceuticals Inc at Cowen Health Care Conference -Breakout Session
Mar 3, 2015
Regeneron Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 8.74% 12.34%
Operating margin 32.50% 28.55%
EBITD margin - 31.60%
Return on average assets 7.54% 10.17%
Return on average equity 11.02% 15.41%
Employees 2,925 -
CDP Score - -

Address

777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron develops new product candidate using VelociSuite technology platforms. Regeneron’s discovery platforms are designed to identify specific proteins of therapeutic interest for a particular disease or cell type and validate these targets through high-throughput production of genetically modified mice using the Company’s VelociGene technology to understand the role of these proteins in normal physiology, as well as in models of disease. The Company also has human monoclonal antibody technology, VelocImmune and cell line expression technology VelociMab. Regeneron’s antibody product candidates in clinical trials were developed using VelocImmune. The Company has three marketed products: EYLEA, ZALTRAP and ARCALYST.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 85
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 51
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Executive Vice President - Research and Development
Age: 58
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Daniel P. Van Plew Senior Vice President, General Manager - Industrial Operations and Product Supply
Age: 42
Bio & Compensation  - Reuters
Michael Aberman M.D. Senior Vice President - Strategy and Investor Relation
Age: 44
Bio & Compensation  - Reuters
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 58
Bio & Compensation  - Reuters
Robert J. Terifay Senior Vice President - Commercial
Age: 55
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. Chief Scientific Officer and President - Regeneron Laboratories, Director
Age: 55
Bio & Compensation  - Reuters